{
    "2019-06-17": [
        [
            {
                "time": "2019-06-17",
                "original_text": "Why Pfizer's Acquisition of Array BioPharma Won't Pay Off Anytime Soon",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Acquisition",
                        "Array BioPharma",
                        "Pay Off",
                        "Soon"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-06-17",
                "original_text": "Pfizer Expands in Cancer With $10.6 Billion Deal for Array",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Cancer",
                        "$10.6 Billion",
                        "Deal",
                        "Array"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "cancer"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-06-17",
                "original_text": "Pfizer's $11 Billion Cancer-Drug Deal Takes Pricey Path to Growth",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "$11 Billion",
                        "Cancer-Drug",
                        "Deal",
                        "Growth"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "cancer"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-06-17",
                "original_text": "Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "High-Growth",
                        "Dividend",
                        "Stock",
                        "Great Choice"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}